1. Home
  2. SCHL vs ARVN Comparison

SCHL vs ARVN Comparison

Compare SCHL & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scholastic Corporation

SCHL

Scholastic Corporation

HOLD

Current Price

$45.46

Market Cap

790.4M

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$7.90

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCHL
ARVN
Founded
1920
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Books
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
790.4M
658.2M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
SCHL
ARVN
Price
$45.46
$7.90
Analyst Decision
Hold
Buy
Analyst Count
1
19
Target Price
$40.00
$15.05
AVG Volume (30 Days)
295.2K
678.1K
Earning Date
03-19-2026
05-04-2026
Dividend Yield
1.99%
N/A
EPS Growth
N/A
58.84
EPS
1.87
N/A
Revenue
$1,487,100,000.00
$262,600,000.00
Revenue This Year
$1.88
N/A
Revenue Next Year
$4.05
N/A
P/E Ratio
$23.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.60
$6.06
52 Week High
$44.54
$14.22

Technical Indicators

Market Signals
Indicator
SCHL
ARVN
Relative Strength Index (RSI) 68.85 44.44
Support Level $37.84 $7.35
Resistance Level N/A $10.18
Average True Range (ATR) 1.28 0.41
MACD 0.06 0.16
Stochastic Oscillator 98.63 62.25

Price Performance

Historical Comparison
SCHL
ARVN

About SCHL Scholastic Corporation

Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: